| Literature DB >> 27411096 |
Esbeidira Aranet Arroyo-Martínez1, Alejandra Meaney1, Gabriela Gutiérrez-Salmeán2, Juan Miguel Rivera-Capello1, Vidal González-Coronado1, Alejandro Alcocer-Chauvet1, Genaro Castillo1, Nayelli Nájera3, Guillermo Ceballos3, Eduardo Meaney3.
Abstract
BACKGROUND: Remote ischemic preconditioning (RIPC) represents an attractive therapy for myocardial protection, particularly when ischemic events can be anticipated. Although several hypothetic mechanisms have been proposed, no definite molecular pathways have been elucidated.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27411096 PMCID: PMC5074068 DOI: 10.5935/abc.20160100
Source DB: PubMed Journal: Arq Bras Cardiol ISSN: 0066-782X Impact factor: 2.000
Demographic and clinical characteristics of patients
| 66.1 | 11.3 | 63 | 6.9 | |
| 26.8 | 4.2 | 27.7 | 4.5 | |
| n | % | n | % | |
| 15 | 65 | 16 | 69 | |
| 16 | 79 | 14 | 60.8 | |
| 19 | 83 | 21 | 91.3 | |
| Aspirin | 23 | 100 | 23 | 100 |
| Clopidogrel | 23 | 100 | 23 | 100 |
| β-blockers | 13 | 57 | 18 | 78 |
| ACEI | 8 | 35 | 13 | 56 |
| ARBs | 11 | 48 | 7 | 30.4 |
| CCB | 5 | 21.7 | 6 | 26 |
| Statins | 19 | 82.6 | 21 | 91.3 |
| Insulin | 5 | 22 | 4 | 17.3 |
| Metformin | 16 | 70 | 11 | 47.8 |
| 11 | 48 | 12 | 52 | |
| 0 | 0 | 0 | 0 | |
| 23 | 100 | 23 | 100 | |
| < 15 (renal failure, stage V) | 3 | 13 | 0 | 0 |
| 15-29 (severe reduction of GFR, stage IV) | 4 | 17.3 | 3 | 13 |
| 30-59 (moderate reduction of GFR, stage III) | 3 | 13 | 4 | 17.3 |
| 60-89 (mild reduction of GFR, stage II) | 7 | 30.4 | 10 | 43 |
| ≥ 90 (normal GFR, stage I) | 6 | 26 | 6 | 26 |
SD: standard deviation; GFR: glomerular filtration rate; ACEI: angiotensin-converting-enzyme inhibitors; ARBs: angiotensin II receptor blockers; CCB: calcium-channels blockers.
Figure 1Local nitric oxide (NOx) corrected by creatinine levels in controls and preconditioned patients. Data are expressed as means ± SEM.
Figure 2Changes in serum concentrations of troponin-I at baseline and 24 hours after percutaneous coronary intervention in control (left) and preconditioning (right) groups. Data are expressed as means ± SEM.
Figure 3Percent changes in summation of R waves on all leads, from baseline to 24 hours after percutaneous coronary intervention (PCI) in control (left) and preconditioning (right) groups
Figure 4Percent changes in summation of R waves on precordial leads, from baseline to 24 hours after percutaneous coronary intervention (PCI) in control (left) and preconditioning (right) groups.
R wave summation in control and experimental groups
| 56.9±139 | 51.3±12.7 | < 0.0001 | 53.3±230 | 62.0±22.4 | 0.006 |
| 36.5±21.8 | 32±17.9 | 0.003 | 33.1±18 | 37.3±19.5 | 0.057 |
SD: standard deviation; PCI: percutaneous coronary interventions.
Serum creatinine and GFR values in control and experimental patients before and after PCI
| 1.28±0.63 | 1.39±0.67 | 0.001 | 1.0±0.32 | 1.17±0.36 | 0.002 |
| GFR mL/min/1.73 m2 | GFR mL/min/1.73 m2 | ||||
| 63±26.5 | 57±23.5 | 0.003 | 72.0±21.1 | 64.4±20.97 | <0.0001 |
Cr: serum creatinine; GFR: glomerular filtration rate; PCI: percutaneous coronary intervention. *No intergroup significant differences were found.